Medtronic has declared its aim to acquire Companion Medical

Medtronic has declared its aim to acquire Companion Medical, an InPen manufacturer, which is a smart insulin pen system approved by the FDA coupled with an integrated diabetes management app.

Medtronic will seek to develop insights and dosing capabilities automation further to help reduce the pressure, regardless of the platform preferred for insulin delivery. Besides that, Medtronic will aim to extend InPen worldwide.

President and Executive Vice President of Medtronic’s diabetes group, Sean Salmon, stated: “This acquisition is an ideal strategic fit for Medtronic, as we further simplify diabetes management and improve outcomes by optimising dosing decisions for the large number of people using multiple daily injection. We look forward to building upon the success of the InPen by combining it with our intelligent algorithms to deliver proactive dosing advice personalised to each individual. This smart CGM system can help people think less about diabetes and be able to live life with more freedom, on their own terms. Our goal is to become a trusted partner that offers consistent support whether an individual wants to stay on MDI, transition to automated insulin delivery or take a break from their pump.”

Companion Medical’s CEO and Co-Founder, Sean Saint, stated: “We are thrilled to be combining our strengths and differentiated product portfolios to work towards serving even more people around the world living with diabetes in the ways that matter most to them. Simplifying diabetes management to reduce burden and improve outcomes has always been our goal and through a respected global leader like Medtronic, we’ll now be able to take InPen to this next phase of growth which is great news for people with diabetes who stand to benefit most.”